- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07774962
Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock (DISCO-SHOCK)
Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock: A Prospective Observational Cohort Study Evaluating Its Prevalence and Prognostic Value
In septic shock, restoring large-vessel (macrocirculatory) perfusion-reflected by a normal capillary refill time (CRT)-does not always mean that oxygen use at the tissue level has recovered. This mismatch, sometimes called loss of hemodynamic coherence, may be detectable by comparing CRT with the oxygen extraction ratio (O₂ER), a marker of how much oxygen the tissues are extracting from the blood. Patients whose CRT has normalized but whose O₂ER remains abnormal-either too high (suggesting oxygen delivery that is insufficient for demand) or too low (suggesting microcirculatory shunting)-are considered to have a "discordant" perfusion phenotype.
This prospective, single-center, observational cohort study aims to determine how often this CRT-O₂ER discordance occurs at the 6th hour of resuscitation in adult patients with septic shock, and whether it is associated with 28-day mortality. Approximately 100 consecutive adult patients diagnosed with septic shock (with pre-existing central venous and arterial catheters) will be followed. Clinical and laboratory measurements-including CRT, O₂ER, lactate, mottling score, and organ dysfunction scores-will be recorded at hours 0, 6, 12, and 24, with the main phenotype grouping performed at hour 6. The study is purely observational: CRT is a painless, non-invasive bedside measurement, and O₂ER is calculated from blood gas samples already drawn as part of routine care, so no additional interventions or blood draws are performed for research purposes.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background. In septic shock resuscitation, improvement of macrocirculatory targets such as blood pressure and capillary refill time (CRT) does not always reflect adequate oxygen utilization at the tissue level-a phenomenon described as loss of hemodynamic coherence. Although the ANDROMEDA-SHOCK trial highlighted CRT-targeted resuscitation, a subset of patients with a normalized CRT may still have impaired tissue oxygen balance. The oxygen extraction ratio (O₂ER) can deviate in two directions: a high O₂ER (>30%) suggests oxygen delivery that is insufficient for demand (e.g., low cardiac output, anemia), whereas a low O₂ER (<20%, with high central venous oxygen saturation) may reflect microcirculatory shunting and cytopathic hypoxia.
Primary aim. To determine the prevalence of the "discordant" phenotype-defined as a normalized CRT with an abnormal O₂ER at hour 6 of resuscitation-and to evaluate its association with 28-day mortality.
Secondary aims. (1) To examine the association between CRT/O₂ER-defined perfusion phenotypes and 28-day mortality, ICU and hospital length of stay, duration of mechanical ventilation, vasopressor-free days, and need for renal replacement therapy; (2) to validate the proposed O₂ER >30% threshold using ROC curve analysis and identify the optimal cut-off for mortality in this cohort; (3) to assess whether the discordant phenotype is an independent predictor of mortality after adjustment for age, APACHE II score, lactate, and noradrenaline dose using multivariable analysis; (4) to examine the relationship of discordance with complementary perfusion markers (lactate clearance, mottling score, venoarterial CO₂ difference).
Design and setting. Prospective, single-center, observational cohort study in an intensive care unit. Consecutive adult patients diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline will be enrolled. Time zero (Hour 0) is defined as the time of vasopressor (noradrenaline) initiation.
Measurements. While patients continue standard care, serial clinical and laboratory measurements are recorded at hours 0, 6, 12, and 24, and organ function at hour 72. CRT is measured in a standardized manner on the ventral surface of the distal phalanx of the right index finger after 10 seconds of firm pressure. O₂ER is calculated as (SaO₂ - ScvO₂) / SaO₂. At hour 6, CRT and blood gas sampling are performed simultaneously (within 15 minutes). Inter-rater reliability of CRT is assessed in the first 20-30 patients by two independent, blinded observers (ICC for continuous values; Cohen's kappa for the ≤3 s normal/abnormal classification).
Phenotype grouping (Hour 6). Group 1 - Concordant normal (CRT ≤3 s + O₂ER 20-30%); Group 2a - Discordant, high O₂ER (CRT ≤3 s + O₂ER >30%); Group 2b - Discordant, low O₂ER (CRT ≤3 s + O₂ER <20%); Group 3 - Concordant abnormal (CRT >3 s + abnormal O₂ER). The primary group of interest is the combined discordant phenotype (Group 2a + Group 2b).
Outcomes. Primary outcome: 28-day mortality (counted from Hour 0). Secondary outcomes: ICU and hospital length of stay, duration of mechanical ventilation, time to vasopressor weaning, vasopressor-free days, hour-72 organ function (SOFA-2, ongoing vasopressor/ventilation, lactate), and need for renal replacement therapy.
Sample size and statistics. A target of approximately 100 consecutive patients was chosen so that an expected discordance prevalence of ~30% can be estimated with a 95% confidence interval half-width of ±9%. Descriptive statistics, normality testing (Shapiro-Wilk), and appropriate parametric/non-parametric group comparisons will be used. The prevalence of the discordant phenotype will be reported with 95% CI. ROC analysis (with AUC) will evaluate the O₂ER threshold for mortality. Multivariable binary logistic regression (parsimonious model: phenotype, APACHE II, lactate; events-per-variable ≈12) will identify independent predictors of mortality, reported as odds ratios with 95% CI. Survival across phenotype groups will be estimated by Kaplan-Meier analysis and compared with the log-rank test. Statistical significance is set at p < 0.05.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tugba Yesilyurt Dogu, Intensive Medicine Care Fellow
- Numéro de téléphone: +9005535150847
- E-mail: tugbaayesilyurt@gmail.com
Lieux d'étude
-
-
-
Istanbul, Turquie (Türkiye)
- Recrutement
- Başakşehir Çam and Sakura City Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline
- Presence of both a central venous catheter and an arterial line
Exclusion Criteria:
- Active bleeding
- Ongoing extracorporeal membrane oxygenation (ECMO)
- Raynaud phenomenon or significant peripheral vascular disease that makes capillary refill time measurement unreliable (e.g., critical ischemia, amputation, digital ulcer/necrosis, or inability to measure on the right index finger)
- Death within the first 6 hours
- Inability to obtain hour-6 CRT or blood gas (phenotyping not possible)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
septic schoc cohort
Consecutive adult patients (≥18 years) admitted to the intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who have pre-existing central venous and arterial catheters.
Patients are prospectively followed while receiving standard care, with serial measurements at hours 0, 6, 12, and 24 (time zero = vasopressor initiation).
At hour 6, patients are classified into perfusion phenotypes based on capillary refill time (CRT) and oxygen extraction ratio (O₂ER): concordant normal, discordant with high O₂ER, discordant with low O₂ER, and concordant abnormal.
The primary group of interest is the combined discordant phenotype (normalized CRT with abnormal O₂ER).
|
Non-invasive, standardized bedside measurement of capillary refill time on the right index finger.
Oxygen extraction ratio calculated as (SaO₂ - ScvO₂)/SaO₂ from routinely obtained arterial and central venous blood gases.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Prevalence of the discordant CRT-O₂ER phenotype
Délai: At hour 6 of resuscitation (6 hours after vasopressor initiation)
|
Proportion of patients classified as having a discordant perfusion phenotype (normalized CRT ≤3 s with an abnormal O₂ER, i.e., >30% or <20%; combined Group 2a + Group 2b) at hour 6, reported with 95% confidence interval.
|
At hour 6 of resuscitation (6 hours after vasopressor initiation)
|
|
28-day all-cause mortality
Délai: 28 days from Hour 0 (vasopressor initiation)
|
All-cause mortality at 28 days, and its association with the hour-6 perfusion phenotype.
|
28 days from Hour 0 (vasopressor initiation)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
ICU length of stay
Délai: Through study completion, up to 28 days
|
Duration of intensive care unit stay in days.
|
Through study completion, up to 28 days
|
|
Hospital length of stay
Délai: Through study completion, up to 28 days
|
Duration of hospital stay in days.
|
Through study completion, up to 28 days
|
|
Duration of mechanical ventilation
Délai: Through study completion, up to 28 days
|
Total days on mechanical ventilation (0 if never ventilated).
|
Through study completion, up to 28 days
|
|
Time to vasopressor weaning
Délai: From Hour 0 up to 28 days
|
Time in hours to sustained vasopressor discontinuation (off ≥24 continuous hours), measured from Hour 0.
|
From Hour 0 up to 28 days
|
|
Vasopressor-free days
Délai: 28 days
|
Number of days alive and free of vasopressor support within 28 days.
|
28 days
|
|
Organ dysfunction at hour 72
Délai: Hour 72
|
SOFA-2 score at hour 72, together with ongoing vasopressor/mechanical ventilation status and lactate level.
|
Hour 72
|
|
Need for renal replacement therapy (RRT)
Délai: Within 28 days
|
Proportion of patients requiring newly initiated RRT within 28 days (chronic dialysis patients excluded from the "new" category).
|
Within 28 days
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diagnostic performance of the O₂ER threshold for mortality
Délai: Hour 6 measurement; mortality at 28 days
|
Discriminative ability of O₂ER for 28-day mortality assessed by ROC analysis (area under the curve), with identification of the optimal cut-off and comparison to the literature threshold of 30%.
|
Hour 6 measurement; mortality at 28 days
|
|
Inter-rater reliability of CRT measurement
Délai: Hour 6, first 20-30 patients
|
Agreement of hour-6 CRT between two independent, blinded observers; intraclass correlation coefficient (ICC) for continuous values and Cohen's kappa for the ≤3 s normal/abnormal classification.
|
Hour 6, first 20-30 patients
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- KAEK-11/29.07.2026.276 (Autre identifiant: BASAKSEHİR CAM AND SAKURA CITY HOSPITAL)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .